IL17A and acute lymphoblastic leukemia: Furthermore, Bi et al. have shown that IL-17A fosters resistance to daunorubicin by activating the Akt signaling pathway, and inhibitors of PI3K/Akt such as LY294002 or perifosine can effectively restore daunorubicin-induced cell death in relapsed B-ALL cells [29].